Home Newsfeeds Raymond James Maintains Outperform on Phreesia, Raises Price Target to $40

Raymond James Maintains Outperform on Phreesia, Raises Price Target to $40

Raymond James analyst John Ransom maintains Phreesia (NYSE:PHR) with a Outperform and raises the price target from $35 to $40.

byBenzinga Newsdesk

December 12, 2022

1 minute read

Raymond James analyst John Ransom maintains Phreesia (NYSE:PHR) with a Outperform and raises the price target from $35 to $40.

Cathie Wood Trims Tesla Stake Ahead Of Next Week’s Stock Split — Loads Up $11M In This Telehealth Stock

By Bhavik Nair

August 18, 6:48 AM

Cathie Wood-led Ark Investment Management bought 311,073 Teladoc Health Inc (NYSE: TDOC) shares valued at over $11 million, through four of its exchange-traded funds, according to the firm's trading disclosure.

ARKK

News

Pliant Therapeutics’ Bexotegrast Meets Primary, Secondary Endpoints in Phase 2a Liver Fibrosis Trial

By Benzinga Newsdesk

September 26, 7:33 AM

Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data from INTEGRIS-PSC, a Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe

PLRX